CDSCO Biological Evaluation & Evidence Support
Independent, founder-led support for India-focused biological-evaluation evidence, file-gap diagnosis, and clinical-readiness handoffs. Execution roles remain separately owned.
Key service strengths
Bounded Evidence Diagnostic
Identify the biological-safety question, evidence state, highest-risk gaps, and the correct owner for the next step.
Biological-Evaluation Readiness
Review how device facts, material and process evidence, testing, BEP/BER logic, and India-facing claims connect.
Clinical-Readiness Boundaries
Separate biological-evidence preparation from clinical investigation, applicant, and submission-execution responsibilities.
Cross-Market Traceability
Reframe existing EU or FDA evidence for India without implying automatic acceptance or duplicating unsupported conclusions.
For teams that need the biological-evidence problem defined before testing or submission work continues
This scope fits manufacturers, importers, startups, and regulatory teams with a real India evidence decision: what the current file supports, what is missing, what can be reused, and which work must be handed to a laboratory, execution provider, applicant, or India regulatory specialist.
Fragmented Biological-Safety Evidence
Device facts, material and process evidence, test reports, risk-management links, and conclusions exist but do not form one traceable India-facing rationale.
BEP or BER Readiness Review
A plan or report exists, but its scope, evidence fitness, biological endpoints, or India-specific reasoning needs an independent bounded review.
Global Evidence Reframing
You want to reuse EU or FDA evidence responsibly while keeping India-specific claims, source hierarchy, and authority decisions explicit.
Clinical-Readiness Handoff Map
You need to distinguish biological-evaluation inputs from clinical investigation, site/QMS, applicant, and formal submission responsibilities.
What medical-device support do I actually need?
Answer five non-confidential questions. The same routing logic separates MedDev Advisory’s evidence and documentation scope from laboratory, manufacturing, licensing, sterilization, packaging, and submission-execution roles.
Choose a direct starting point
If the guided questions do not load, use these ordinary links. Do not send confidential files before appropriate safeguards are in place.
Four India workstreams that should not be blurred together
MedDev Advisory can own a bounded biological-evidence review. Site/QMS/licensing, external execution, laboratory qualification, applicant, and submission roles need their own qualified owners.
1. Biological-Evidence Review
MedDev Advisory scope: define the biological-evaluation question; review evidence fitness, BEP/BER logic, material and process links, and India-facing traceability.
2. Site, QMS & Licensing
Separate qualified owner: facility registration, site QMS implementation, licensing, importer/applicant structure, and formal regulatory representation are not delivered here.
3. Manufacture, Sterilization & Packaging
Separate execution provider: manufacturing, sterilization processing or validation, and sterile-packaging validation stay external. MedDev can review their biological-evidence consequences.
4. Testing-Laboratory Qualification
Separate laboratory owner: laboratory selection, qualification, quotations, methods, and testing are not performed here. Scientific judgment is not linked to any referral incentive.
Clinical-Readiness Handoff
The diagnostic can show which biological-evidence gaps affect clinical-readiness planning, while clinical investigation and submission decisions remain with the responsible qualified parties and CDSCO.
Independence Safeguard
MedDev Advisory is not a lab, manufacturer, certifier, sterilization or packing provider, authorised representative, applicant or submission agent, or regulator—and does not promise an approval outcome.
Current primary-source checks include the CDSCO Gazette index and final G.S.R. 743(E) and 744(E). The links open CDSCO-hosted sources.
Diagnose the evidence need before assigning the wider India work
The first step uses non-confidential facts to decide whether a biological-evidence diagnostic is appropriate—or whether the matter should stop and move to a different qualified owner.
Share a Non-Confidential Summary
Provide the device category, intended body contact, immediate India decision, current document inventory, and target timing. Do not send device files initially.
Run the Initial Diagnostic
Map the biological-evaluation question, available evidence, traceability gaps, assumptions, and the smallest useful next output.
Stop or Re-Scope Where Needed
Move site/QMS/licensing, external execution, laboratory qualification, clinical investigation, applicant, and filing work to the appropriate owner.
Agree the Defined Workstream
Proceed only with written inputs, deliverables, responsibilities, review boundaries, timing, and the next handoff clearly defined.
Common questions before starting a CDSCO-related scope
Are you affiliated with or endorsed by CDSCO?
No. MedDev Advisory is an independent, founder-led consulting practice and is not affiliated with, endorsed by, or approved by CDSCO or the Government of India.
Do you act as the applicant or submission agent?
No. MedDev Advisory does not act as an authorised representative, applicant, submission agent, certifier, or regulator. Those roles must be contracted separately where required.
Do you perform testing, sterilization, packaging, or manufacturing?
No. MedDev Advisory is not a laboratory, manufacturer, sterilization provider, packing provider, or execution vendor. The scope can assess how external work affects the biological-evidence file.
What can the first review actually deliver?
A bounded requirement-and-evidence diagnostic: current-state evidence map, prioritized gaps, assumptions, recommended owner, and a stop or re-scope decision before a larger engagement.
Define the biological-evaluation question before India execution work creates rework.
Send only a non-confidential device category, intended contact, immediate India decision, current document inventory, and target timing. I will confirm whether a bounded biological-evidence diagnostic fits—or whether another qualified owner should lead.